HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives

Valentina Fanotto, Elena Ongaro, Karim Rihawi, Antonio Avallone, Nicola Silvestris, L. Fornaro, E. Vasile, L. Antonuzzo, Francesco Leone, G. Rosati, Francesco Giuliani, Roberto Bordonaro, Mario Scartozzi, Giovanna De maglio, Francesca V. Negri, Gianpiero Fasola, Giuseppe Aprile

Research output: Contribution to journalReview article

Abstract

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

Original languageEnglish
Pages (from-to)69060-69074
Number of pages15
JournalOncotarget
Volume7
Issue number42
Publication statusPublished - Aug 12 2016

Keywords

  • Colorectal cancer
  • Gastric cancer
  • HER2-inhibition
  • Predictive factor
  • Prognosis

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives'. Together they form a unique fingerprint.

  • Cite this

    Fanotto, V., Ongaro, E., Rihawi, K., Avallone, A., Silvestris, N., Fornaro, L., Vasile, E., Antonuzzo, L., Leone, F., Rosati, G., Giuliani, F., Bordonaro, R., Scartozzi, M., De maglio, G., Negri, F. V., Fasola, G., & Aprile, G. (2016). HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives. Oncotarget, 7(42), 69060-69074.